[go: up one dir, main page]

ES2109982T3 - Procedimiento y composiciones de ensayo para determinar proteasas en suero, particularmente proteina c activada. - Google Patents

Procedimiento y composiciones de ensayo para determinar proteasas en suero, particularmente proteina c activada.

Info

Publication number
ES2109982T3
ES2109982T3 ES92306108T ES92306108T ES2109982T3 ES 2109982 T3 ES2109982 T3 ES 2109982T3 ES 92306108 T ES92306108 T ES 92306108T ES 92306108 T ES92306108 T ES 92306108T ES 2109982 T3 ES2109982 T3 ES 2109982T3
Authority
ES
Spain
Prior art keywords
activated protein
procedure
test compositions
proteases
serum proteases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92306108T
Other languages
English (en)
Inventor
John H Griffin
Andras Gruber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2109982T3 publication Critical patent/ES2109982T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un procedimiento para determinar la cantidad de una proteasa en un muestra de un fuido corporal, que comprende las etapas de: a) poner en contacto un composición de moléculas de anticuerpos inmovilizados, que comprende moléculas de anticuerpos fijas a un soporte sólido, con un inhibidor irreversible de proteasas en una cantidad de inhibidor suficiente para inhibir la actividad de proteasas asociada con la composición, para formar una primera mezcla, teniendo las citadas moléculas de anticuerpos capacidad para inmunorreaccionar con una proteasa para formar un complejo de inmunorreacción que tiene actividad de proteasas y capacidad para unirse a un inhibidor reversible; b) mantener la primera mezcla durante un período de tiempo suficiente para que el citado inhibidor irreversible inhiba la actividad de proteasas de la composición de moléculas de anticuerpos inmovilizados y se forme una composición de anticuerpos inmovilizados exenta de actividad de proteasas; c) separar de la composición de anticuerpos inmovilizados exenta de actividad de proteasas, formada en la etapa (b), el exceso de inhibidor irreversible; d) mezclar una muestra de un fuido corporal con un tampón inhibidor de la coagulación que contiene una cantidad inhibidora de proteasas de un inhibidor reversible de proteasas, para formar una segunda mezcla; e) mezclar la citada segunda mezcla con la composición de anticuerpos exenta de actividad de proteasas, formada en la etapa (c), para formar una mezcla de inmunorreacción que tiene una fase líquida y una fase sólida; f ) mantener la citada mezcla de inmunorreacción en condiciones de inmunorreacción durante un período de tiempo suficiente para que la proteasa presente en la citada muestra corporal inmunorreaccione con las moléculas de anticuerpos presentes sobre el citado soporte sólido y se forme un primer producto de inmunorreacción de fase sólida; g) separar del citado primer producto de inmunorreacción de fase sólida el inhibidor reversible para formar un productode inmunorreacción de fase sólida exento de inhibidor; y h) determinar la cantidad de actividad de proteasas presente en el producto de inmunorreacción de fase sólida exento de inhibidor, formado en la etapa (g), y por lo tanto, la cantidad de proteasa en la muestra corporal.
ES92306108T 1991-07-03 1992-07-02 Procedimiento y composiciones de ensayo para determinar proteasas en suero, particularmente proteina c activada. Expired - Lifetime ES2109982T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/725,359 US5288612A (en) 1991-07-03 1991-07-03 Assay methods for detecting serum proteases, particularly activated protein C

Publications (1)

Publication Number Publication Date
ES2109982T3 true ES2109982T3 (es) 1998-02-01

Family

ID=24914223

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92306108T Expired - Lifetime ES2109982T3 (es) 1991-07-03 1992-07-02 Procedimiento y composiciones de ensayo para determinar proteasas en suero, particularmente proteina c activada.

Country Status (9)

Country Link
US (1) US5288612A (es)
EP (2) EP0528525B1 (es)
AT (1) ATE160876T1 (es)
CA (1) CA2112702C (es)
DE (1) DE69223355T2 (es)
DK (1) DK0528525T3 (es)
ES (1) ES2109982T3 (es)
GR (1) GR3025752T3 (es)
WO (1) WO1993001309A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002822A1 (en) * 1990-08-06 1992-02-20 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
US6099843A (en) * 1991-02-12 2000-08-08 Heska Corporation Parasitic helminth PLA2 proteins
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US6146870A (en) * 1991-12-13 2000-11-14 Heska Corporation Flea protease proteins
US6156556A (en) * 1991-12-13 2000-12-05 Heska Corporation Flea protease proteins, nucleic acid molecules, and uses thereof
US6150125A (en) * 1991-12-13 2000-11-21 Heska Corporation Flea protease proteins and uses thereof
US6121035A (en) * 1991-12-13 2000-09-19 Heska Corporation Flea aminopeptidase proteins and uses thereof
US5972645A (en) * 1991-12-13 1999-10-26 Heska Corporation Flea serine protease nucleic acid molecules
US6210920B1 (en) 1991-12-13 2001-04-03 Heska Corporation Flea protease proteins, nucleic acid molecules, and uses thereof
CA2088222A1 (en) * 1992-10-20 1994-04-21 Nabil G. Seidah Development of research, diagnostic and production tools for pro-hormone convertases
US5416003A (en) * 1993-04-14 1995-05-16 Litmus Concepts, Inc. Reporter enzyme release technology: methods of assaying for the presence of aspartic proteases and other hydrolytic enzyme activities
NL9301134A (nl) * 1993-06-29 1995-01-16 Inst Voor Agrotech Onderzoek Werkwijze voor het detekteren en eventueel kwantificeren van aktiviteit van ten minste één protease-inhibitor in een te analyseren mengsel, alsmede toepassing van de werkwijze voor het bepalen van de (rest)aktiviteit van één (of meer) afzonderlijke (iso)type(s) protease-inhibitor(en) en toepassing van de werkwijze voor het bepalen van de totale (rest)aktiviteit van een mengsel eventueel na een verwerkingsproces zoals een proces ter verwijdering of inaktivatie van protease-inhibitor(en).
ATE177536T1 (de) * 1993-06-30 1999-03-15 Diagnostische Forsch Stiftung Messung des aktivierten partiellen thromboplastinzeit (aptt) in einer einstufen- reaktion
US6159746A (en) * 1994-03-29 2000-12-12 Gruppo Lepetit S.P.A. Solid phase immunoassay to detect inhibitors of proteolytic enzymes
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6214579B1 (en) 1994-10-18 2001-04-10 Heska Corporation Flea leucine aminopeptidase nucleic acid molecules and uses thereof
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6139840A (en) * 1995-10-18 2000-10-31 Heska Corporation Methods of eliciting an antibody response using flea protease proteins and homologs thereof
US6204010B1 (en) 1995-06-07 2001-03-20 Heska Corporation Flea protease proteins, nucleic acid molecules, and uses thereof
IL120704A0 (en) * 1996-04-24 1998-04-05 Heska Corp Flea protease proteins nucleic acid molecules and uses thereof
DE19820328A1 (de) * 1998-05-07 1999-11-11 Roche Diagnostics Gmbh Verfahren und Reagenz zum Nachweis apoptotischer Zellen bzw. einer bei Apoptose aktivierten Protease
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
FR2785053A1 (fr) * 1998-10-21 2000-04-28 Centre Nat Rech Scient Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) et de detection de l'activite inhibitrice ou activatrice d'un inhibiteur ou d'un activateur de cette enzyme
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
EP1989304B1 (en) * 2006-02-24 2010-05-05 Novo Nordisk Health Care AG A method of removing a non-metallic protein inhibitor from a liquid pharmaceutical preparation
EP3715356B1 (en) 2009-12-18 2023-10-11 CSL Limited Method of purifying polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4112064A (en) * 1977-02-22 1978-09-05 Hoffmann-La Roche Inc. Stabilized angiotensin I solutions
US4387166A (en) * 1981-09-15 1983-06-07 Anda Biologicals Immunoassay wherein immune complex forms and ages for at least one hour
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system

Also Published As

Publication number Publication date
AU652474B2 (en) 1994-08-25
ATE160876T1 (de) 1997-12-15
EP0595865A1 (en) 1994-05-11
DE69223355D1 (de) 1998-01-15
EP0528525A1 (en) 1993-02-24
AU2317492A (en) 1993-02-11
US5288612A (en) 1994-02-22
EP0595865A4 (en) 1994-06-22
DK0528525T3 (da) 1998-02-23
EP0528525B1 (en) 1997-12-03
GR3025752T3 (en) 1998-03-31
CA2112702C (en) 2004-06-08
DE69223355T2 (de) 1998-05-28
CA2112702A1 (en) 1993-01-21
WO1993001309A1 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
ES2109982T3 (es) Procedimiento y composiciones de ensayo para determinar proteasas en suero, particularmente proteina c activada.
DE60128249D1 (de) Verfahren zur diagnose von immunologischer lebensmittelsensitivität
ATE254765T1 (de) Blutgerinnsel-detektor
ATE205884T1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
EP0805215A3 (en) Diagnostic methods and probes
ATE339688T1 (de) Diagnostische tests und kits für clostridium difficile
WO2008041953A3 (en) Dengue diagnosis and treatment
WO2002046746A3 (en) Method for detection of vitamin d metabolites
ATE403153T1 (de) Test zum direkten nachweisen einer rs virus bezogenen biologischen zelle in einer körperflüssigkeitsprobe
DK104093D0 (da) Fremgangsmaade til bestemmelse af collagen-fragmenter i legemsvaesker, test-kit og midler til udoevelse af fremgangsmaaden og anvendelse af fremgangsmaaden til diagnosticering af lidelser associeret til collagen-metabolismen
DE60225802D1 (de) Verfahren und gerät zum nachweis des gesamten proteingehaltes bei niedrigen ph-werten
ATE258310T1 (de) Testverfahren für collagenpeptid
DE60233107D1 (de) Teststreifen enthaltend Kontrollmittel und Zeitsetzermittel
DE69809640D1 (de) Methode zum Nachweis eines Analyten durch Immunchromatographie
DE60123755D1 (de) Komplementierungsassay für den nachweis von protein-löslichkeit und -faltung
ATE462975T1 (de) Verfahren zum immunochemischen testen des anti- hm1.24-antikörpers
WO2001090408A3 (fr) Detection et caracterisation de l'activite de proteines impliquees dans la reparation de lesions de l'adn
CA2213083A1 (en) Detection of antibody production
CA2585816A1 (en) Colorimetric strip containing coomassie blue for semi-quantitation of albumin
ATE247831T1 (de) Verfahren zum nachweis von autoimmun-pathologien
DE69730223D1 (de) Diagnostische methode zum nachweis von isoformen des eosinophilen kationischen proteins
CA2344762A1 (en) Tests for the rapid evaluation of ischemic states and kits
WO2004054431A3 (en) Tests for the rapid evaluation of ischemic states and kits
WO2001027621A3 (en) Competitive inhibition elisa for antibody detection
DE69920981D1 (de) Knorpelresorptionsassays

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 528525

Country of ref document: ES